211 related articles for article (PubMed ID: 22150825)
21. A two-stage phase II trial design utilizing both primary and secondary endpoints.
Lin X; Allred R; Andrews G
Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
[TBL] [Abstract][Full Text] [Related]
22. Formal statistical testing and inference in randomized phase II trials in medical oncology.
Saad ED; Sasse EC; Borghesi G; Miranda VC; Fede AB; Saad LS; Oliveira V; Barros EA; Pascoin M; Del Giglio A; Riechelmann R
Am J Clin Oncol; 2013 Apr; 36(2):143-5. PubMed ID: 22307212
[TBL] [Abstract][Full Text] [Related]
23. Two-stage k-sample designs for the ordered alternative problem.
Shan G; Hutson AD; Wilding GE
Pharm Stat; 2012; 11(4):287-94. PubMed ID: 22408050
[TBL] [Abstract][Full Text] [Related]
24. Incorporating toxicity considerations into the design of two-stage phase II clinical trials.
Bryant J; Day R
Biometrics; 1995 Dec; 51(4):1372-83. PubMed ID: 8589229
[TBL] [Abstract][Full Text] [Related]
25. Adaptive two-stage designs for single-arm phase IIA cancer clinical trials.
Lin Y; Shih WJ
Biometrics; 2004 Jun; 60(2):482-90. PubMed ID: 15180674
[TBL] [Abstract][Full Text] [Related]
26. Using the partitioning principle to adaptively design dose-response studies.
Ling X; Hsu J
J Biopharm Stat; 2006; 16(5):733-43. PubMed ID: 17037268
[TBL] [Abstract][Full Text] [Related]
27. Admissible two-stage designs for phase II cancer clinical trials.
Jung SH; Lee T; Kim K; George SL
Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
[TBL] [Abstract][Full Text] [Related]
28. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
29. Designing phase II studies in cancer with time-to-event endpoints.
Owzar K; Jung SH
Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
[TBL] [Abstract][Full Text] [Related]
30. Phase II multi-step planning methods in oncology: comparison, recommendations and potential applications.
Medioni J; de Rycke Y; Tournoux Facon C; Mallet A; Asselain B
Contemp Clin Trials; 2007 May; 28(3):249-57. PubMed ID: 17113357
[TBL] [Abstract][Full Text] [Related]
31. Adaptive two-stage designs in phase II clinical trials.
Banerjee A; Tsiatis AA
Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
[TBL] [Abstract][Full Text] [Related]
32. A three-outcome design for randomized comparative phase II clinical trials.
Hong S; Wang Y
Stat Med; 2007 Aug; 26(19):3525-34. PubMed ID: 17262879
[TBL] [Abstract][Full Text] [Related]
33. Sample size determination for phase II clinical trials based on Bayesian decision theory.
Stallard N
Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
[TBL] [Abstract][Full Text] [Related]
34. Optimal two-stage randomized multinomial designs for Phase II oncology trials.
Sun LZ; Chen C; Patel K
J Biopharm Stat; 2009; 19(3):485-93. PubMed ID: 19384690
[TBL] [Abstract][Full Text] [Related]
35. An exact method for analysis following a two-stage phase II cancer clinical trial.
Jovic G; Whitehead J
Stat Med; 2010 Dec; 29(30):3118-25. PubMed ID: 21170906
[TBL] [Abstract][Full Text] [Related]
36. Exact two-stage designs for phase II activity trials with rank-based endpoints.
Wilding GE; Shan G; Hutson AD
Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
[TBL] [Abstract][Full Text] [Related]
37. Dose-finding design driven by efficacy in onco-hematology phase I/II trials.
Seegers V; Chevret S; Resche-Rigon M
Stat Med; 2011 Jun; 30(13):1574-83. PubMed ID: 21394754
[TBL] [Abstract][Full Text] [Related]
38. Group-sequential methods for adaptive seamless phase II/III clinical trials.
Stallard N
J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
[TBL] [Abstract][Full Text] [Related]
39. Bayesian design of single-arm phase II clinical trials with continuous monitoring.
Johnson VE; Cook JD
Clin Trials; 2009 Jun; 6(3):217-26. PubMed ID: 19528131
[TBL] [Abstract][Full Text] [Related]
40. Current issues in oncology drug development, with a focus on Phase II trials.
Sargent DJ; Taylor JM
J Biopharm Stat; 2009; 19(3):556-62. PubMed ID: 19384696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
